New treatment trial aims to protect people with rare immune deficiencies
NCT ID NCT06954441
Summary
This study is testing a new immunoglobulin product called V-IMMUNE® for people with primary immunodeficiency (PID), a condition where the body cannot make enough antibodies to fight infections. About 50 participants, aged 2 and older who are already receiving similar treatments, will switch to V-IMMUNE® infusions every three weeks for one year. The main goals are to see if it effectively prevents serious bacterial infections and is safe to use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCIES (PID) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IMIP Centro de Pesquisa
RECRUITINGRecife, Pernanbuco, 50070-902, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.